title: Individualized management of advanced bladder cancer: Where do we stand?
abstract: Despite recent progress in the development of novel targeted therapies in various malignancies, the management of advanced urothelial cancer has changed little over the past 2 decades. Comorbidities inherent to patients with bladder cancer often preclude the use of standard cisplatin-based chemotherapy and underscore the need for individualized treatment recommendations and the development of more effective therapies. This review discusses current issues relevant to the management of patients with locally advanced and metastatic urothelial carcinoma of the bladder and highlights recent advances in defining molecular aberrations that may ultimately lead to personalized therapeutic decision making.
authors: Levine Cancer Institute, Carolinas HealthCare System, Charlotte, NC. Electronic address: earle.burgess@carolinas.org.
authors: Earle F
authors: EF
authors: Burgess
mesh_terms: D002295:Carcinoma, Transitional Cell / Q000628:therapy*; D006801:Humans; D057285:Precision Medicine / Q000379:methods / Q000639:trends*; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
keywords: Bladder Cancer; Molecular profiling; Personalized medicine; Urothelial; p53